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Abstract
MUC1 mucin is transcriptionally regulated by estrogen,
progesterone, and glucocorticoids. Our objective was to
determine whether androgen receptor (AR) activation
regulates expression of MUC1. The following breast and
prostatic cell lines were phenotyped and grouped
according to AR and MUC1 protein expression: 1)
AR+MUC1+ [DAR17+19 (AR transfectants of DU-145) ,
ZR-75-1, MDA-MB-453, and T47D]; 2) ARMUC1+
[DZeo1 (AR vector control ) , DU-145, BT20,MDA-MB-
231, andMCF7]; 3) AR+MUC1 (LNCaP and LNCaP-r) .
Cell proliferation was determined using the MTT assay
in the presence of synthetic androgen R1881, 0.1 pM
to 1 M. Cell surface MUC1 expression was deter-
mined by flow cytometry in the presence or absence
of oestradiol, medroxy progesterone acetate or R1881,
with and without 4 hydroxy-flutamide (4 -OH) , a
nonsteroidal AR antagonist. The functional signifi-
cance of MUC1 expression was investigated with a
cell–cell aggregation assay. Only AR+ MUC1+ cell
lines showed a significant increase in MUC1 expres-
sion with AR activation (P ( range) =.01 to .0001) ,
reversed in the presence of 4-OHF. Cell proliferation
was unaffected. Increased expression of MUC1 was
associated with a significant (P ( range) =.002 to .001)
reduction in cell–cell adhesion. To our knowledge,
this is the first description of androgen-dependent
regulation of MUC1 mucin. This is also functionally
associated with decreased cell–cell adhesion, a
recognised feature of progressive malignancy. These
findings have important implications for physiological
and pathological processes.
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Introduction
Mucins are major constituents of the glycocalyx — a
predominantly negatively charged, highly glycosylated pro-
tein coat expressed at the luminal surface of glandular
epithelia. Recently, the 14th mucin gene was described [1] ,
although MUC1 mucin (syn: polymorphic epithelial mucin,
sialomucin, episialin ) remains the most extensively inves-
tigated [2,3] . A common feature of all mucin genes is a
tandem repeat region, which in the case of MUC1 is a 20–
amino acid sequence, repeated 30 to 120 times [2] . Mucins
can be broadly grouped into those with (e.g., MUC1, MUC3,
and MUC4) or without (e.g., MUC2, MUC5AC, MUC5B,
MUC6) a transmembrane domain, resulting in the mucin
being either membrane-bound or secreted. MUC1 mucin,
however, is unique among mucins because of its ubiquitous
expression by all glandular epithelia. Splice variants of the
MUC1 gene have been identified, including secreted MUC1
( lacking the C-terminal membrane spanning subunit ) and
MUC1/Y, which lacks the tandem repeat region [4,5] .
In vitro studies have demonstrated a number of different
properties of MUC1, which have been correlated with
physiological or pathological processes. These include 1)
interference with immune surveillance by cancer cells
through an immunosuppressive effect on T cells [6 ] ; 2)
inhibition of cell–cell and cell–matrix adhesion, which has
been correlated to tumour progression [7] , and also control
of blastocyst implantation [8] ; 3) signal transduction via the
cytoplasmic tail, which has also been associated with
inhibition of cell–cell adhesion [9] ; 4) sequestration of
 -catenin through interactionwith the cytoplasmic tail [10] ; 5)
induction of glandular morphogenesis by epithelial cells [11] ;
and 6) heterotypic cell–cell adhesion through binding to
specific ligands, such as the selectins [12] and ICAM-1
[13] , which may facilitate intravascular cancer metastasis.
Hormonal regulation of MUC1 has been demonstrated in a
number of organ systems. Cyclical change of endometrial
MUC1 expression in animal models has been extensively
documented, and may play an important role in determining
the receptivity of endometrium to embryo implantation [8] .
Recently, progesterone dependent regulation of MUC1 has
also been demonstrated in human endometrium, although
the effect was the opposite to that seen in animal models
[14] . In human breast cancer cell lines, addition of estrogen
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and progesterone is associated with increased MUC1
expression [15] and glucocorticoid-dependent upregulation
of MUC1 has been documented in DU-145, a prostatic cell
line, and multiple myeloma lines [16] . There are, however,
no data in the literature examining the role of androgens in
the regulation of MUC1 expression.
Androgen receptor (AR) expression has been reported in
up to 50% to 80% of breast [17,18] , ovarian [19] , and
endometrial [18] carcinomas, and 80% or more of prostatic
adenocarcinomas is initially androgen-sensitive [20] . A role
for androgens in the regulation of MUC1 may have
considerable clinical significance. Our objective was to
investigate whether ligand-mediated activation of the AR
modulates MUC1 protein expression.
Materials and Methods
Cell Culture
All cell lines were grown in phenol red free RPMI 1640
[ Imperial Cancer Research Fund ( ICRF), London, UK] ,
containing penicillin–streptomycin–amphotericin B mixture
at a final concentration of 100 U, 100 g, and 0.25 g/ml,
respectively, supplemented with 10% fetal bovine serum
(FBS) (Gibco Life Technologies, Paisley, Scotland) .
LNCaP and DU-145 were purchased from American
Type Cell Culture (ATCC, Manassas, VA). LNCaP-r was a
generous gift from Dr. Van Steenbrugge (Department of
Urology, Erasmus University, Rotterdam, Holland) . MCF7,
T47D, MDA-MB-231, MDA-MB-453, BT20, and ZR-75-1
were obtained from the ICRF (Lincoln’s Inn Fields, London,
UK) . DAR17 and 19 are two transfectants of the DU-145 cell
line, which constitutively express human AR under the
control of the CMV promoter, and DZeo1, the vector control,
is transfected with plasmid lacking AR. Details of transfection
and characterisation are reported elsewhere [21] . Cells
were maintained in standard cell culture incubation con-
ditions in humidified air with 10% C02 supplementation at
378C. Cells were split at 80% confluence using trypsin /
versene as previously reported [22] . Cells were routinely
subcultured at 1:6, and medium changed every 72 hours.
Sex Steroid Receptor Agonists and Antagonist
Sex steroid receptor agonists: 17 -hydroxy-5 -an-
drostan-3-one (dihydro- testosterone: DHT) , 17 -hy-
droxy-17 -methyl -estra-4,9,11- trien-3-one (R1881 — a
nonmetabolised AR agonist ) , 17 -estradiol (E2), and 6 -
methyl 17 -hydroxy-progesterone acetate (medroxy pro-
gesterone acetate: MPA) were diluted to stock solutions
of 1000 final concentration desired in 100% ethanol, and
stored at 208C. Sex steroids were obtained from Sigma
(Poole, Dorset, UK), except for R1881, which was obtained
from NEN Life Science Products (Zaventem, Belgium). For
negative controls, an equal volume of ethanol vehicle alone
was added at a final concentration of 0.1% v/v. Sex steroids
were tested for effect on MUC1 expression between 0.1 and
10 nM. Following this, DHT, R1881, and MPA were used at
1 nM, and oestradiol (E2) at 10 nM, which are comparable to
concentrations established in previous reports [15,23,24]
and physiological ranges [25] . The time course of MUC1
response was tested with the addition of sex steroids for 12,
24, 36, 48, 72, and 96 hours.
4-Hydroxy flutamide (4-OHF) was a generous gift from
AstraZeneca pharmaceuticals, and was also stored as a
stock solution of 1000 in ethanol; the final concentration
used in all experiments was 1 M as described previously
[26] . In experiments in which both 4-OHF and steroid
agonist were added, 4-OHF was added 6 hours prior to the
addition of sex steroid.
Antibodies
The antibodies used, their sources, and dilutions are
detailed in Table 1.
Immunocytochemistry ( ICC)
All reagents were of molecular grade and were obtained
from BDH/Merck (Poole, Dorset, UK), unless otherwise
stated. Cells were cultured on four well slides (Hendley,
Loughton, Essex, UK) in medium containing steroids, as
described above, for 48 hours, washed in phosphate-
buffered saline (PBS) (pH 7.4±0.2) , and fixed in methanol
at 48C for 15 minutes. Slides were incubated in washing
medium (final concentrations of 3% horse serum, 1% bovine
serum albumin, 0.05% Tween 20, 0.5 M NaCl in PBS) for
2 hours at room temperature (RT) [27] , after which 75 l of
antibody (see Table 1) was added and incubated overnight
at 48C. CK8/18 are constitutively expressed by glandular
epithelial cells [22] and served as positive controls. Slides
were washed three times, then incubated with fluorescein-
labeled secondary antibody at RT for 2 hours in the dark.
Slides were washed and dried in the dark at RT and
counterstained with propidium iodide–containing Vecta-
shield (Vector Laboratories, Burlingame, CA, USA). UV
light photography (Olympus BX60) was performed within a
week of preparation. ICC was used to screen cell lines for the
presence of AR, and determine expression of MUC1 prior to
flow cytometry.
Table 1. Source and Dilutions for Antibodies Used in this Study.
Source Minimum Epitope Dilution Factors
ICC FC
Primary antibodies
HMFG1 [47 ] DTRP [48,49 ] 10–50 10
HMFG2 [47 ] DTR [48,49 ] 1–10 1
SM3 [50 ] PDTRP [49,51 ] 1–10 1
C595* RPAP [49 ] 100 200
ARy human AR 100
LE61 [52 ] CK8 /18 dimer
( shared epitope ) [ 52 ]
10
Secondary antibody
FITCz rabbit anti mouse 500 50
Abbreviations: ICC — immunocytochemistry; FC — flow cytometry; FITC
— fluorescein isothyanate; HRP — horseradish peroxidase.
*Serotec (Kidlington, Oxford, UK ) .
yBiogenex, distributed by Menarini Diagnostics (Finchampstead, UK ) .
zDako (High Wycombe, Bucks, UK ) .
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Cell Proliferation Assay
For cell proliferation studies, cells were plated at a density
of 3000 cells /well in 96-well plates (Corning, New York,
USA) and were allowed to recover for 4 hours prior to the
addition of the appropriate concentration of R1881. The final
concentration of ethanol was 0.1 l /well. Ethanol vehicle
was added in the same concentration to control wells.
Following incubation was 10 l. 3 - [4,5-Dimethylthiazol -2-
yl ] -2,5-diphenyltetrazolium bromide (MTT) stock solution
(5 mg/ml diluted in phenol red- free RPMI) was added to
each well, and incubated at 378C, 5% CO2 for 4 hours. The
medium was removed, and insoluble formazan crystals were
solubilized with 100 l of acidic isopropanol (0.1 N HCl in
absolute isopropanol ) per well according manufacturer’s
protocol (Sigma) . Plates were shaken for 5 minutes and
absorbance measured at 570 nm on a BioRad 550 micro-
plate reader (BioRad, Hemel Hempstead, UK).
Flow Cytometry
Cells were plated in T75 culture flasks and allowed to
attach overnight, prior to addition of steroid /ethanol vehicle,
and the flasks incubated for 12 to 72 hours. Cells were
detached using versene only ( ICRF) plus gentle agitation,
and washed twice at 48C using washing buffer (PBSA
containing 1% FBS, 1 mM CaCl2, and 1 mM MgCl2) .
Samples were then resuspended in 75 l of primary antibody
(Table 1) per sample, and incubated at 48C for 1 hour. One
additional sample per cell line was incubated with PBS
instead of antibody, which served as a negative control.
Following washing, samples were resuspended in 300 l of
secondary antibody, and incubated at 48C for 45 minutes.
Following further washing, samples were resuspended in
500 l of washing buffer. Flow cytometric analysis was
performed on a Coulter Epics XL (Coulter Electronics,
Luton, UK). Gating parameters were set to exclude clumped
or dead cells, and 20,000 events within the gated area were
counted per individual experiment.
Cell Aggregation Assay
Cell–cell adhesion was determined using a previously
described protocol [28] with minor modifications. Cells were
cultured in the presence of steroids for 72 hours, detached
from plates with versene only, passed through a 24-gauge
needle, and resuspended in Ca2+ /Mg2+ free PBS. Cell
density was determined by automated cell counting (Multi-
sizer II; Coulter Electronics) . 106 cells were then resus-
pended in 1.5 ml of RPMI/FBS 1% with appropriate steroids
and incubated on a shaking platform at 150 rpm at 378C. At
appropriate time points, the percentage of clumped and
single cells was determined by cell counting using a
haemocytometer (Neubauer Improved; Weber Scientific
International, Sussex, UK). Dead cells were excluded by
trypan blue staining. Counts were performed in quadrupli-
cate for each time point.
Statistical Analysis
Flow cytometric data were analysed as follows. Clumped
or apoptotic cells were excluded by gating. Sample size for
each experiment was constant (20,000 cells ) . The plot of
fluorescent intensity versus frequency was integrated to
obtain the area under the curve, corresponding to overall
MUC1 expression in each sample. Absolute levels of MUC1
expression varied with different cell lines and MUC1
antibodies. To allow comparison, MUC1 expression with
each of the different steroid protocols (4OHF, R1881,
4OHF/R1881, MPA, 4OHF/MPA, E2) was expressed as a
percentage of MUC1 expression in control medium (which
was set at 100%). These were analysed using a one-way
ANOVA on log10 transformed data. If the ANOVA indicated
significant difference (P<.05) between steroid protocols,
the estimated marginal means for each steroid, expressed
as a ratio of control medium, and 95% CI were examined to
indicate where the significant differences lay with respect to
control medium.
Cell aggregation data were analysed by regression
analysis using ANOVA with time as the covariate,
assessing steroid, and timesteroid interaction terms to
indicate differences in intercept and slope for different
steroids. All analyses were performed on SPSS version 9
(Chicago, USA) . The significance level was set at
P=.05.
Results
AR/MUC1 Expression Status
All cell lines were phenotyped for expression of AR and
MUC1 proteins in control medium using ICC, and results are
summarised in Table 2. DU-145 and its derivatives all
expressed heterogeneous membranous and diffuse cyto-
plasmic MUC1 recognised by HMFG1. A comparable pattern
Table 2. Summary of Basal Antigen Expression in the Absence of Added
Exogenous Steroid.
(A ) Prostatic Cell Lines
Antibody DU145 DAR17 DAR19 DZeo1 LNCaP LNCaP - r
HMFG1 + + (het ) + + (het ) + + (het ) + + (het )  
HMFG2  *  *  *  *  
C595 + + (het ) + + (het ) + + (het ) + + (het )  
SM3  *  *  *  *  
AR  + + + +  + + +
LE61 + + + + + + + + + + + +
(B ) Breast Cell Lines
Antibody MDA-
MB-231
BT20 T47D MCF7 ZR-75 -1 MDA-
MB -453
HMFG1 + + (het ) + + + + + + + + +
HMFG2 ± + + + + ±
C595 + + (het ) + + + + + + + + +
SM3 + (het ) + + + + + + ±
AR   +  + + + +
LE61 + + + + + + + + + + + +
(A ) Cell lines derived from PC. (B ) Cell lines derived from breast cancer.
( + + /  ) Give a guide as to comparative intensity of immunostaining. ( het ) :
heterogeneous expression.
*Heterogeneous weak immunofluorescence seen with HMFG2 and SM3 at
10 times higher concentration ( 1:1 ) .
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of expression was detected using C595. MUC1 expression
wasnotdetected inanyof theprostatic cell linesusingHMFG2
or SM3 at 1:10 dilution, with minimal expression seen at 1:1
dilution. LNCaP and LNCaP-r were both negative for MUC1
with all antibodies consistent with our previous report [22] .
MUC1 expression was observed in all breast cell lines with
HMFG1, HMFG2, SM3, and C595. The flow cytometry data
were consistent with ICC for all cell lines with the exception
Figure 1. Effect of exogenous androgen (R1881 ) on proliferation of AR+ (DAR17 ) and AR (DZeo1 ) cells. Proliferation in control medium (N.med ) was
compared with proliferation in the presence of R1881 over a concentration range of 10 13 to 10 6 M, and also 4 -hydroxyflutamide (4 -OHF ) . None of the
exogenous steroids has any effect on the proliferation of DZeo1. In contrast, there is an increasing inhibitory effect of R1881 on the growth of DAR19 first apparent at
10 nM. The decline in cell number seen in both cell lines from 150 hours onwards is a result of serum starvation.
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Figure 2. Effect of exogenous steroids on membrane expression of MUC1 mucin. In each graph, log10 ( change in MUC1 expression ) is shown compared to control
medium. (A ) AR+ cell lines demonstrate a significant increase in membranous expression of MUC1 in the presence of R1881 or MPA, which is blocked in the
presence of AR antagonist 4 -OHF. (B ) Representative results (HMFG2 and C595 ) obtained in AR+ (T47D and ZR -75 -1 ) and AR (MCF -7 ) breast cell lines
using different antibodies to MUC1. A comparable increase of membrane MUC1 expression is seen in the presence of R1881 and MPA with different the antibodies.
Expression in MCF7 is not affected by AR agonist or antagonist. In each graph, boxes represent interquartile range and error bars show confidence interval. Circles
represent outlier values (1.5 to 3 boxlengths from interquartile range ) and asterisks represent extreme values ( greater than three boxlengths from interquartile
range ) . For statistical analysis, see Table 3.
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of MDA-MB-231 and -453, both of which expressed
extremely low levels of membrane-associated MUC1.
On the basis of their expression profile, cell lines were
grouped as follows:
1. (AR+MUC1+ ): DAR17, DAR19, ZR-75-1, T47D,
MDA-MB-453;
2. (ARMUC1+ ) : DU-145, DZeo1, MCF-7, BT20,
MDA-MB-231; and
3. (AR+MUC1 ) : LNCaP, LNCaP-r.
Effects of Exogenous Androgens on Proliferation
Before investigating the effect of androgens on MUC1
expression, we assessed whether they were mitogenic or
inhibitory over the concentration range 1013 to 106 M.
It was found that R1881 exerted no effect on cell pro-
liferation until 10 nM and above. Representative results
are shown in Figure 1. For all subsequent experiments,
DHT, R1881, or MPA were added at a final concentration
of 1 nM.
Effects of Exogenous Steroids on MUC1 Expression
Flow cytometric analysis of cells incubated with sex
steroids revealed increased MUC1 expression after 12 hours
and maximal expression by 72 hours (data not shown). On
the basis of this, we incubated all cell lines with sex steroids
for 72 hours. Initial experiments performed with DHT and
Table 3. Summary of Statistical Significance Obtained from Pooled Flow Cytometry Data.
Cell Line ANOVA Pr Steroid Mean Increase CI Pr
HMFG1
DAR17 F ( 5,59 ) =17.229 < .0001 R1881 0.443 (0.348, 0.537 ) < .0001
MPA 0.440 (0.314, 0.566 ) < .0001
DAR19 F ( 5,79 ) =25.510 < .0001 R1881 0.455 (0.381, 0.530 ) < .0001
MPA 0.495 (0.393, 0.596 ) < .0001
ZR -75 -1 F ( 5,45 ) =11.738 < .0001 R1881 0.180 (0.122, 0.238 ) < .0001
MPA 0.191 (0.133, 0.249 ) < .0001
T47D F ( 5,27 ) =7.843 < .0001 R1881 0.506 (0.362, 0.649 ) < .0001
MPA 0.330 (0.160, 0.500 ) .008
DU-145 F ( 5,37 ) =1.660 .169
DZeo1 F ( 5,38 ) =2.158 .079 MPA 0.048 (0.011, 0.085 ) .005
MCF7 F ( 5,16 ) =0.613 .699
BT20 F ( 5,24 ) =0.050 .998
C595
DAR17 F ( 5,18 ) =46.913 < .0001 R1881 0.301 (0.249, 0.353 ) < .0001
MPA 0.311 (0.260, 0.363 ) < .0001
DAR19 F ( 5,29 ) =13.751 < .0001 R1881 0.437 (0.320, 0.554 ) < .0001
MPA 0.348 (0.221, 0.474 ) < .0001
ZR -75 -1 F ( 5,24 ) =13.060 < .0001 R1881 0.388 (0.279, 0.497 ) < .0001
MPA 0.337 (0.228, 0.447 ) < .0001
T47D F ( 5,12 ) =10.706 < .0001 R1881 0.377 (0.248, 0.507 ) .001
MPA 0.450 (0.320, 0.579 ) < .0001
MCF7 F ( 5,12 ) =0.148 .977
HMFG2
ZR-75 -1 F ( 5,18 ) =11.094 < .0001 R1881 0.325 (0.215, 0.436 ) .002
MPA 0.297 (0.186, 0.407 ) .004
T47D F ( 5,17 ) =7.330 .001 R1881 0.307 (0.183, 0.430 ) .003
MPA 0.343 (0.219, 0.466 ) .001
MCF7 F ( 5,11 ) =0.847 .545
BT20 F ( 5,6 ) =0.067 .995
SM3
ZR-75 -1 F ( 5,45 ) =12.989 < .0001 R1881 0.390 (0.279, 0.500 ) .007
MPA 0.450 (0.333, 0.567 ) .001
E2 0.171 (0.061, 0.282 ) .003
T47D F ( 5,27 ) =4.866 .003 R1881 0.255 (0.142, 0.367 ) .001
MPA 0.272 (0.149, 0.395 ) .001
MCF7 F ( 5,16 ) =2.542 .071 R1881 0.090 (0.040, 0.156 ) .048
BT20 F ( 5,12 ) =0.584 .712
The significance of added steroids was assessed with ANOVA. Where this showed a significant outcome (P< .05 ) , the estimated marginal means with their 95%
CI were examined. Mean increase= log10 ( increase in MUC1 expression as ratio of control ) .
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R1881 were similar, and R1881 was subsequently used in all
experiments.
Group 1 ARþMUC1þð Þ:
DAR17; DAR19; ZR751; MDAMB453; T47Dð Þ
Flow cytometric analysis of membranous MUC1 expres-
sion using four different antibodies (see below) showed that
all cell lines except MDA-MB-453 expressed membrane-
associated MUC1, and that MUC1 expressed by DAR17 and
-19 was not recognised by HMFG2 or SM3. Addition of
R1881 or MPA to group 1 (AR+MUC1+ ) cell lines was
associated with a significant increase ( <.0001) (Figure 2A,
Table 3) in membranous expression of MUC1 with the
exception of MDA-MB-453, in which membrane-associated
MUC1 could not be detected. Oestradiol had no effect on
membranous MUC1 expression (Figure 2A ) . To ensure
reproducibility and specificity, MUC1 expression was ana-
lysed with four different antibodies (each recognises a
different epitope in the tandem repeat region; Table 1) .
Although there was some variation in the magnitude, a
consistent response to exogenous androgens was seen
(Table 3) . None of the cell lines demonstrated any change in
MUC1 expression with the addition of ethanol vehicle alone.
Group 2 ARMUC1þð Þ :
DU145; DZeol; MCF7; BT20; MDAMB231ð Þ
All cell lines except for MDA-MB-231 expressed mem-
brane-associated MUC1. Addition of sex steroid receptor
Figure 3. Representative results of cell – cell aggregation assay. Aggregation of prostatic (DAR19 and DU-145 ) and breast (MDA-MB-453 and ZR-75 -1 ) cell
lines with time in the presence of 4 -OHF, R1881, or 4 -OHF+R1881. AR+ cell lines (DAR19 and ZR -75 -1 ) demonstrate reduced cell aggregation in the presence
of R1881, which is blocked in the presence of 4 -OHF. ARMUC1+ (e.g., DU -145 ) cell lines do not demonstrate any change in cell aggregation in the presence of
R1881 and /or 4 -OHF. MDA-MB -453, which is AR+MUC1+ but does not express cell surface MUC1, also does not show any demonstrable change in cellular
aggregation in the presence of androgens, consistent with this effect being mediated by cell surface MUC1. Results with each steroid protocol were compared with
regression analysis. Statistically significant results are indicated. The differences between DAR19 and ZR -75 -1 are attributed to different kinetics of cellular
aggregation in each cell line.
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agonists was not associated with a significant increase in
MUC1 (Table 3 and Figure 2B ) .
Group 3 ARþMUC1ð Þ : LNCap; LNCap r
No MUC1 was detectable in these cell lines, and
addition of R1881, MPA, and E2 did not induce MUC1
expression.
Effects of AR Blockade
Addition of 4-OHF abolished R1881- and MPA-mediated
increase in MUC1 in the group 1 (AR+MUC1+ ) cell lines
(Figure 2A ) . Expression of MUC1 in group 2
(ARMUC1+ ) was unaffected by the addition of 4OHF
(Figure 2B ) . 4-OHF was without effect when added to
control medium alone, or in the presence of E2.
Cellular Aggregation
To investigate the functional significance of increased
MUC1 expression in the group 1 cell lines, we analysed
cellular aggregation in the presence of R1881 and/or 4-
OHF. Aggregation was significantly inhibited in group 1
(AR+MUC1+ ) cell lines DAR17, DAR19 (P<.001) , and
ZR-75-1 (P<.002) when cells were incubated in the
presence of R1881 (Figure 3 ) . The antiadhesive effect
was abrogated when 4-OHF was added together with
R1881. 4-OHF did not have any effect when added to
control medium. MDA-MB-453 (AR+MUC1+ ) , which
expresses minimal cell surface MUC1, did not demonstrate
any change in cell adhesion in the presence of R1881, 4-
OHF, or both. Cellular aggregation in the groups 2
(ARMUC1+ ) and 3 (AR+MUC1 ) cell lines was
unaffected by any of the steroid protocols.
Discussion
In the early 1990s, several groups identified consensus
sequences for estrogen, progesterone, and glucocorticoid
steroid response elements on the human MUC1 pro-
moter. However, in the intervening years, only a few
studies have further explored the effect of steroids on
MUC1 expression. Treon et al. [16] demonstrated
dexamethasone-mediated increase in surface MUC1 in
a variety of multiple myeloma and adenocarcinoma cell
lines [16] . A regulatory role for ovarian steroids on
MUC1 in endometrium has also been reported in a
variety of animals including human, rabbit, and mouse
[8,14,29] .
In this report, we have demonstrated that ligand
activation of the AR causes a significant increase in
membrane-associated MUC1 (P<.0001) in AR+MUC1+
breast and prostatic cell lines but not in ARMUC1+ or
AR+MUC1 cell lines. This observed increase in MUC1
was abrogated when cells were incubated in the presence of
4OHF, an AR antagonist. Our data demonstrate that ligand
activation of the AR upregulates membrane-associated
MUC1. A search of the human MUC1 gene promoter
sequence [30] for previously reported androgen responsive
elements (ARE) [31] identified several partial consensus
sequences, two of which are shown below:
There are several mechanisms by which MUC1 is thought
to influence cell adhesion. The extracellular domain of
MUC1 can extend 500 nm or more from the cell surface. Its
length, rigidity, and negative charge result in steric hindrance
and electrostatic repulsion, masking the interactions of much
smaller membrane-associated molecules [32,33] . The
cytoplasmic tail of MUC1 is able to sequester  - and  -
catenin, which may influence the cadherin /catenin system
[10] . In addition, the cytoplasmic tail of MUC1 also interacts
with the EGFR pathway [9] and its overexpression was
associated with increased activity of MAPK — a down-
stream effector of EGFR ligand binding. One known
consequence of increased MAPK activity is negative
regulation of tight junction formation [9] . In breast cancer
[7 ] and melanoma [33] cell lines, cell–cell adhesion may
be virtually absent as a result of high MUC1 expression,
even with high levels of E-cadherin expression. Abrogation
of MUC1 expression restores cellular aggregation without
any change in expression level of E-cadherin. Our data
reveal a significant decrease in aggregation in the presence
of R1881 (P<.001) , consistent with an antiadhesive role
mediated by MUC1. It is conceivable that the observed
reduction in cellular aggregation could be mediated by other
molecules. However, our data on MDA-MB-453 (AR+
MUC1+ ), which expresses cytoplasmic MUC1 but virtually
no membranous MUC1, and LNCaP-r (AR+MUC1 ) su-
ggest that the likely reason is an alteration in the expression
of cell surface MUC1. The exact mechanism governing the
antiadhesive effect requires further investigation.
Overexpression of MUC1 has been described in most
human adenocarcinomas, including lung [34] , stomach
[35] , and most extensively in breast cancer [36] . It has
been associated with prognostic indicators of poor clinical
outcome, including lymph node metastasis, blood vessel
invasion [37] , early recurrence following surgical resection
[34] , and overall disease-specific survival [35] reflecting its
multifunctional nature. Increased serum androgens [38] or
urinary androgen metabolites [39] have been correlated to
increased risk of postmenopausal breast cancer, disease
recurrence [40] , or rate of disease progression [41] .
Menopausal androgen replacement therapy (MART) in
symptomatic women following natural or surgical meno-
pause is in current clinical practice [42] . In light of our data, it
is conceivable that MART administration may create a
steroid environment in which occult glandular malignancy
may progress through the actions of MUC1. The majority of
ovarian, endometrial, and breast adenocarcinomas are AR+
[17–19] , and approximately 80% of prostatic adenocarci-
nomas are sensitive to androgen deprivation therapy on
initial presentation [20] . MUC1 expression has been
correlated to pathological stage and Gleason grade in
(+20 )
Consensus ARE
GCCTGAATCTGTTCT ( +40 )
GGTACANNNTGTTCT
(2546 )
Probasin ARE-2 [32 ]
AGTCCTCCCAGACCC (2532 )
AGTACTCCAAGAACC
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prostate cancer [43] . The androgen-dependent regulation
of MUC1 in androgen-sensitive carcinomas is a potentially
important area of investigation.
In animal models investigated thus far, endometrial MUC1
is expressed in the prereceptive phase and its down-
regulation by progesterone coincides with the receptive
phase [8,29] . Whereas in the human endometrium the
converse is observed, MUC1 is expressed throughout the
menstrual cycle and its mRNA levels increase several fold in
the post ovulatory phase, consistent with transcriptional
regulation by progesterone [14] . Okon et al. compared the
plasma androgen concentrations in women with recurrent
miscarriage to fertile controls and correlated this with the
endometrial protein PP14. They found that levels of both
testosterone and androstenedione were higher in the
recurrent miscarriage group [44] . Current understanding of
embryo implantation suggests that MUC1 is important in this
process and alterations of this glycoprotein could signifi-
cantly impact successful implantation of the embryo
[14,45,46] .
In summary, our study provides evidence for receptor -
mediated upregulation of MUC1 protein expression by
androgen in an in vitro model of hormone-responsive
(prostate and breast ) cancer. This is the first report
exploring androgen-dependent regulation of MUC1 in any
organ system. The majority of breast, ovarian, endometrial,
and prostate cancers are AR+ and (with the exception of
prostate) the function of AR is not clear. Given that
overexpression of MUC1 has been correlated with poor
prognostic features in many adenocarcinomas, androgen-
dependent regulation of MUC1 may be important in AR+
tumours as well as normal physiological processes and
merits further study.
References
[1] Yin BW, and Lloyd KO (2001 ) . Molecular cloning of the CA125 ovarian
cancer antigen: Identification as a new mucin (MUC16 ) . J Biol Chem
276, 27371–27375.
[2] Seregni E, Botti C, Massaron S, Lombardo C, Capobianco A, Bogni A,
and Bombardieri E ( 1997 ) . Structure, function and gene expression of
epithelial mucins. Tumori 83, 625–632.
[3] Lagow E, DeSouza MM, and Carson DD ( 1999 ) . Mammalian
reproductive tract mucins. Hum Reprod Update 5, 280–292.
[4] Baruch A, Hartmann M, Yoeli M, Adereth Y, Greenstein S, Stadler Y,
Skornik Y, Zaretsky J, Smorodinsky NI, Keydar I, and Wreschner DH
(1999 ) . The breast cancer –associated MUC1 gene generates both a
receptor and its cognate binding protein. Cancer Res 59, 1552–1561.
[5] Hanisch FG, and Muller S (2000 ) . MUC1: the polymorphic appearance
of a human mucin. Glycobiology 10, 439–449.
[6] Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA,
Freeman GJ, Park SY, Watanabe M, Gong J, Hayes DF, Kufe DW, and
Nadler LM (1996 ) . Breast cancer –associated antigen, DF3 /MUC1,
induces apoptosis of activated human T cells. Nat Med 2, 1367–1370.
[7] Kondo K, Kohno N, Yokoyama A, and Hiwada K (1998 ) . Decreased
MUC1 expression induces E - cadherin–mediated cell adhesion of
breast cancer cell lines. Cancer Res 58, 2014–2019.
[8] Hewetson A, and Chilton BS (1997 ) . Molecular cloning and hormone -
dependent expression of rabbit Muc1 in the cervix and uterus. Biol
Reprod 57, 468–477.
[9] Schroeder JA, Thompson MC, Gardner MM, and Gendler SJ ( 2001 ) .
Transgenic MUC1 interacts with epidermal growth factor receptor and
correlates with mitogen -activated protein kinase activation in the
mouse mammary gland. J Biol Chem 276, 13057–13064.
[10] Yamamoto M, Bharti A, Li Y, and Kufe D (1997 ) . Interaction of the
DF3 /MUC1 breast carcinoma–associated antigen and beta - catenin in
cell adhesion. J Biol Chem 272, 12492–12494.
[11] Hudson MJ, Stamp GWH, Chaudhary KS, Hewitt R, Stubbs AP, Abel
PD, and Lalani E -N (2001 ) . Human MUC1 mucin: a potent glandular
morphogen. J Pathol 194, 373–383, (DOI: 10.1002 /path.898 ) .
[12] Mannori G, Crottet P, Cecconi O, Hanasaki K, Aruffo A, Nelson RM,
Varki A, and Bevilacqua MP (1995 ) . Differential colon cancer cell
adhesion to E - , P - , and L -selectin: role of mucin - type glycoproteins.
Cancer Res 55, 4425–4431.
[13] Kam JL, Regimbald LH, Hilgers JH, Hoffman P, Krantz MJ, Long-
enecker BM, and Hugh JC (1998 ) . MUC1 synthetic peptide inhibition
of intercellular adhesion molecule - 1 and MUC1 binding requires six
tandem repeats. Cancer Res 58, 5577–5581.
[14] Meseguer M, Aplin JD, Caballero -Campo P, O’Connor JE, Martin JC,
Remohi J, Pellicer A, and Simon C (2001 ) . Human endometrial mucin
MUC1 is up - regulated by progesterone and down - regulated in vitro by
the human blastocyst. Biol Reprod 64, 590–601.
[15] McGuckin MA, Quin RJ, and Ward BG (1998 ) . Progesterone
stimulates production and secretion of MUC1 epithelial mucin in
steroid - responsive breast cancer cell lines. Int J Oncol 12, 939–
945.
[16] Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje
N, Hilgers JHM, Nadler L, Belch AR, Pilarski LM, and Anderson KC
(1999 ) . Muc -1 core protein is expressed on multiple myeloma cells
and is induced by dexamethasone. Blood 93, 1287–1298.
[17] Hall REA, Horsfall DJ, Birrell SN, JM B, Sutherland RL, and Tilley WD
(1996 ) . Expression of the androgen receptor and androgen - respon-
sive protein, apolipoprotein D, in human breast cancer. Br J Cancer 74,
1175–1180.
[18] Hackenberg R, and Schulz KD (1996 ) . Androgen receptor –mediated
growth control of breast cancer and endometrial cancer modulated by
antiandrogen - and androgen - like steroids. J Steroid Biochem Mol Biol
56, 113–117.
[19] Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, and Scoccia
B (1997 ) . Expression of epidermal growth factor and androgen
receptors in ovarian cancer. Gynecol Oncol 66, 250–254.
[20] Stenner J, and Crawford DE (1999 ) . Combined Androgen Blockade. In
Prostate Cancer. Pathology, Diagnosis and Treatment. AV Kaisary, GP
Murphy, L Denis, and K Griffiths (Eds ) . Martin Duntz, London. pp.
303–317.
[21] Chaudhary KS, Nightingale J, Stubbs AP, Stamp GWH, Abel PD, and
Lalani E -N (1998 ) . Ligand mediated inhibition of cell proliferation, and
apoptotic cell death in DU145 prostatic adenocarcinoma cell line
expressing full length androgen receptor complementary deoxyribonu-
cleic acid. Eur Urol 34, 251.
[22] Mitchell S, Abel P, Ware M, Stamp G, and Lalani E ( 2000 ) . Phenotypic
and genotypic characterization of commonly used human prostatic cell
lines. BJU Int 85, 932–944.
[23] Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ,
and Tilley WD (1995 ) . Androgens induce divergent proliferative
responses in human breast cancer cell lines. J Steroid Biochem Mol
Biol 52, 459–467.
[24] Hall RE, Birrell SN, Tilley WD, and Sutherland RL (1994 ) . MDA-MB-
453, an androgen - responsive human breast carcinoma cell line with
high level androgen receptor expression. Eur J Cancer 4, 484–490.
[25] Giles AM, and Holloway P (1996 ) . Reference Intervals for Biochemical
Data. In Oxford Textbook of Medicine ( 3rd ed., vol. 3 ) . DJ Weatherall,
JGG Ledingham, DA Warrell ( Eds ) . Oxford Univ. Press, Oxford.
[26] Terouanne B, Tahiri B, Georget V, Belon C, Poujol N, Avances C, Orio
FJ, Balaguer P, and Sultan C (2000 ) . A stable prostatic biolumines-
cent cell line to investigate androgen and antiandrogen effects.Mol Cell
Endocrinol 160, 39–49.
[27] Nightingale J ( 2000 ) . Investigation of androgen receptor gene
transfection into human prostate cancer cells. Effect on cellular growth,
apoptosis and adhesion. PhD Thesis. London University, London. 322
pp.
[28] Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotoh B, Takeichi M, and
Nagai Y (1993 ) . p60v - src causes tyrosine phosphorylation and
inactivation of the N - cadherin–catenin cell adhesion system. EMBO
J 12, 307–314.
[29] Surveyor GA, Gendler SJ, Pemberton L, Das SK, Chakraborty I, Julian
J, Pimental RA, Wegner CC, Dey SK, and Carson DD (1995 ) .
Expression and steroid hormonal control of Muc -1 in the mouse uterus.
Endocrinology 136, 3639–3647.
[30] Kovarik A, Lu PJ, Peat NMJ, and Taylor -Papadimitriou J ( 1996 ) .
Two GC boxes (Sp1 sites ) are involved in regulation of the activity of
Neoplasia . Vol. 4, No. 1, 2002
Regulation of Human MUC1 Mitchell et al. 17
the epithelium - specific MUC1 promoter. J Biol Chem 271, 18140–
18147.
[31] Funder JW ( 1993 ) . Importance of Steroidogenesis in Specific
Hormone Action. In Steroid Hormone Action. MG Parker (Ed ) . Oxford
Univ. Press, Oxford. pp. 26–44.
[32] Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, and Hilkens J
(1995 ) . Episialin (MUC1 ) overexpression inhibits integrin -mediated
cell adhesion to extracellular matrix components. J Cell Biol 129,
255–265.
[33] Wesseling J, van der Valk SW, and Hilkens J (1996 ) . A mecha-
nism for inhibition of E - cadherin–mediated cell – cell adhesion by
the membrane -associated mucin episialin /MUC1. Mol Biol Cell 7,
565–577.
[34] Ohgami A, Tsuda T, Osaki T, Mitsudomi T, Morimoto Y, and Higashi T,
Yasumoto K (1999 ) . MUC1 mucin mRNA expression in stage I lung
adenocarcinoma and its association with early recurrence. Ann Thorac
Surg 67, 810–814.
[35] Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko
T, Tanaka S, Irimura T, Kim YS, and Sato E (1998 ) . Expression of
MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the
prognosis of the patients. Clin Cancer Res 4, 2605–2614.
[36] McGuckin MA, Walsh MD, Hohn BG, Ward BG, and Wright RG (1995 ) .
Prognostic significance of MUC1 epithelial mucin expression in breast
cancer. Hum Pathol 26, 432–439.
[37] Nakagawa K, Akagi J, Takai E, Tamori Y, Okino T, Kako H, Egami H,
and Ogawa M (1999 ) . Prognostic values of MUC -1 molecule
expressing cytokine receptor - like epitope and DF3 in patients with
gastric carcinoma. Int J Oncol 14, 425–435.
[38] Dorgan J, Boudou P, Stanczyk FZ, Longcope CTA, Falk RT, Schusler
N, and Stephenson HE ( 2001 ) . Sources of elevated serum
androgens in postmenopausal women who develop breast cancer
(Abstract ) . Proc AACR 92nd Annu Meet (March 2001, #4086 ) 42,
761.
[39] Wang DY, Allen DS, De Stavola BL, Fentiman IS, Brussen J, Bulbrook
RD, Thomas BS, Hayward JL, and Reed MJ ( 2000 ) . Urinary
androgens and breast cancer risk: results from a long - term prospective
study based in Guernsey. Br J Cancer 82, 1577–1584.
[40] Ballerini P, Oriana S, Duca P, Martinetti A, Venturelli E, Ferrari L,
Dolci S, and Secreto G (1993 ) . Urinary testosterone as a marker of
risk of recurrence in operable breast cancer. Breast Cancer Res Treat
26, 1 –6.
[41] Bulbrook RD, and Thomas BS (1989 ) . Hormones are ambiguous risk
factors for breast cancer. Acta Oncol 28, 841–847.
[42] Slayden S (1998 ) . Risks of menopausal androgen supplementation.
Semin Reprod Endocrinol 16, 145–152.
[43] Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, and
Levine AC (1999 ) . MUC1 expression in prostate carcinoma: correla-
tion with grade and stage. Mol Urol 3, 163–168.
[44] Okon MA, Laird SM, Tuckerman EM, and Li TC (1998 ) . Serum
androgen levels in women who have recurrent miscarriages and their
correlation with markers of endometrial function. Fertil Steril 69, 682–
690.
[45] Horne AW, White JO, Margara RA, Williams R, Winston RM, and Lalani
E ( 2001 ) . MUC1: a genetic susceptibility to infertility? Lancet 357,
1336–1337.
[46] Horne AW, White JO, and Lalani EN (2000 ) . The endometrium and
embryo implantation. A receptive endometrium depends on more than
hormonal influences. BMJ 321, 1301–1302.
[47] Taylor Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL,
and Bodmer WF (1981 ) . Monoclonal antibodies to epithelium -specific
components of the human milk fat globule membrane: production and
reaction with cells in culture. Int J Cancer 28, 17–21.
[48] Briggs S, Price MR, and Tendler SJ ( 1991 ) . Immune recognition of
linear epitopes in peptide fragments of epithelial mucins. Immunology
73, 505–507.
[49] Petrakou E, Murray A, Rosamund C, Graves L, and Price MR (1998 ) .
Evaluation of Pepscan analyses for epitope mapping of anti -MUC1
monoclonal antibodies — a comparative study and review of five
antibodies. Anticancer Res 18, 4419–4421.
[50] Burchell J, Gendler S, Taylor Papadimitriou J, Girling A, Lewis A, Millis
R, and Lamport D (1987 ) . Development and characterization of breast
cancer reactive monoclonal antibodies directed to the core protein of
the human milk mucin. Cancer Res 47, 5476–5482.
[51] Dokurno P, Bates PA, Band HA, Stewart LMD, Lally JM, Burchell JM,
Taylor Papadimitriou J, Snary D, Sternberg MJE, and Freemont PS
(1998 ) . Crystal structure at 1.95 A resolution of the breast tumour -
specific antibody SM3 complexed with its peptide epitope reveals novel
hypervariable loop recognition. J Mol Biol 284, 713–728.
[52] Waseem A, Lane EB, Harrison D, and Waseem N (1996 ) . A keratin
antibody recognizing a heterotypic complex: epitope mapping to
complementary locations on both components of the complex. Exp
Cell Res 223, 203–214.
[53] Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA,
Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS, et al. ( 1993 ) .
Characterization of two cis -acting DNA elements involved in the an-
drogen regulation of the probasin gene. Mol Endocrinol 7(1), 23–36.
18 Regulation of Human MUC1 Mitchell et al.
Neoplasia . Vol. 4, No. 1, 2002
